Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 16/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333829 | 1.00 | XPO1 (0.73) | XPO1HDAC1HDAC6MAPTDYRK3 | |
| SCHEMBL1333830 | 1.00 | XPO1 (0.73) | XPO1HDAC1HDAC6MAPTDYRK3 | |
| SCHEMBL12130572 | 0.89 | XPO1 (0.68) | XPO1HDAC1HDAC6 | |
| SCHEMBL12130573 | 0.89 | XPO1 (0.68) | XPO1HDAC1HDAC6 | |
| SCHEMBL1336042 | 0.89 | XPO1 (0.85) | XPO1 | |
| SCHEMBL12128329 | 0.89 | XPO1 (0.85) | XPO1 | |
| SCHEMBL1336048 | 0.89 | XPO1 (0.85) | XPO1 | |
| SCHEMBL15542842 | 0.88 | XPO1 (0.69) | XPO1HDAC1HDAC6 | |
| SCHEMBL15542841 | 0.88 | XPO1 (0.69) | XPO1HDAC1HDAC6 | |
| SCHEMBL18402944 | 0.87 | XPO1 (0.78) | XPO1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3074007-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BETA-THALASSEMIAS | INST NAT SANTE RECH MED (FR) | 2019-07-03 | — | — | EP | claimed |
| US-20170020847-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BETA-THALASSEMIAS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-01-26 | — | — | US | claimed |
| EP-3074007-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BETA-THALASSEMIAS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-10-05 | — | — | EP | claimed |
| WO-2015079031-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BETA-THALASSEMIAS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-06-04 | — | — | WO | claimed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | claimed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20210308106-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC MASTOCYTOSIS | UNIVERSITÉ PARIS CITÉ (FR) | 2021-10-07 | — | — | US | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2542089-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011109799-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109799-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | XPO1 202/4885HDAC1 493/4885HDAC6 526/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | XPO1 202/4885HDAC1 493/4885HDAC6 526/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | XPO1 202/4885HDAC1 493/4885HDAC6 526/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | XPO1 1481/4885HDAC1 163/4885HDAC6 1109/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | XPO1 2842/4885HDAC1 194/4885HDAC6 1572/4885 |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | XPO1 1/4885HDAC1 434/4885HDAC6 1967/4885 |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | XPO1 1/4885HDAC1 434/4885HDAC6 1967/4885 |
| US-20210308106-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC MASTOCYTOSIS | XPOT, XPO1, XPO4 | XPO1 2/4885HDAC1 3109/4885HDAC6 2301/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | XPO1 202/4885HDAC1 493/4885HDAC6 526/4885 |
| US-20170020847-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BETA-THALASSEMIAS | XPO1, XPOT, XPO6 | XPO1 1/4885HDAC1 3066/4885HDAC6 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.